biomedicines

IMPACT FACTOR 4.7

Indexed in: PubMed

CITESCORE 3.7

an Open Access Journal by MDPI

The Interplay of Gut Dysbiosis with Metabolic Syndrome

Guest Editor:

Dr. Shailendra Pratap Singh
New York Medical Research Scientist, New York Medical College, New York, NY, USA

Deadline for manuscript submissions:
closed (31 January 2024)

Message from the Guest Editor

Dear Colleagues,

Dysbiosis of the gut microbiota plays a crucial role in the pathogenesis of metabolic syndrome. Dysbiosis causes a cluster of interrelated physiological, biochemical, clinical, and metabolic risk factors that are associated with an increased likelihood of developing cardiovascular disease and type 2 diabetes. The main characteristics of metabolic syndrome are elevated blood pressure, dyslipidemia (defined as increased triglycerides and reduced high-density lipoprotein cholesterol), elevated fasting glucose, and central obesity. Manipulation of gut microbiota through the administration of prebiotics or probiotics could reduce intestinal low-grade inflammation and improve gut barrier integrity, thereby improving metabolic balance and promoting weight loss. However, additional evidence is required to fully comprehend their clinical impact and the therapeutic application of dysbiosis and its link with metabolic syndrome.

We invite researchers working on the effects of gut dysbiosis on metabolic syndrome to submit original research articles or review papers for this Special Issue in order to advance our understanding of this complicated and intriguing topic.

biomedicines

IMPACT FACTOR 4.7 | Indexed in: PubMed | CITESCORE 3.7

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI